Supernus Pharmaceuticals (NASDAQ:SUPN) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a report issued on Wednesday,Zacks reports. The brokerage issued a strong-buy rating on the specialty pharmaceutical company’s stock.

A number of other equities analysts also recently issued reports on the company. Piper Sandler assumed coverage on Supernus Pharmaceuticals in a research note on Wednesday. They set an “overweight” rating and a $47.00 price target for the company. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Weiss Ratings lowered Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. Finally, Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $67.00 to $87.00 and gave the company an “overweight” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $63.50.

Supernus Pharmaceuticals Stock Down 2.2%

SUPN traded down $0.58 during trading on Wednesday, hitting $26.16. 5,911,223 shares of the company’s stock were exchanged, compared to its average volume of 1,089,129. Supernus Pharmaceuticals has a fifty-two week low of $25.92 and a fifty-two week high of $42.81. The stock has a market cap of $1.52 billion, a P/E ratio of 7.31, a PEG ratio of 1.19 and a beta of 0.52. The business’s 50 day moving average is $41.02 and its two-hundred day moving average is $46.81.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14). The business had revenue of $208.60 million for the quarter, compared to analyst estimates of $217.56 million. Supernus Pharmaceuticals had a negative net margin of 5.07% and a positive return on equity of 12.99%. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.80) earnings per share. On average, sell-side analysts forecast that Supernus Pharmaceuticals will post 3.15 earnings per share for the current year.

Supernus Pharmaceuticals Announces Dividend

The company also recently declared a special dividend, which was paid on Friday, November 6th. Investors of record on Friday, October 30th were issued a dividend of $8.13 per share.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. increased its position in shares of Supernus Pharmaceuticals by 235.3% during the third quarter. Russell Investments Group Ltd. now owns 287,607 shares of the specialty pharmaceutical company’s stock valued at $10,311,000 after acquiring an additional 201,840 shares during the last quarter. Maryland State Retirement & Pension System boosted its position in Supernus Pharmaceuticals by 52.2% in the third quarter. Maryland State Retirement & Pension System now owns 12,842 shares of the specialty pharmaceutical company’s stock worth $460,000 after purchasing an additional 4,402 shares during the last quarter. Illinois Municipal Retirement Fund grew its stake in Supernus Pharmaceuticals by 1.4% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 31,359 shares of the specialty pharmaceutical company’s stock valued at $1,124,000 after purchasing an additional 440 shares during the period. Equitec Proprietary Markets LLC bought a new position in Supernus Pharmaceuticals in the 3rd quarter valued at $143,000. Finally, Pictet Asset Management Holding SA grew its stake in Supernus Pharmaceuticals by 0.6% in the 3rd quarter. Pictet Asset Management Holding SA now owns 434,915 shares of the specialty pharmaceutical company’s stock valued at $19,116,000 after purchasing an additional 2,437 shares during the period. Institutional investors own 60.33% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.